Sotiropoulos G C, Kaiser G M, Lang H, Molmenti E P, Beckebaum S, Fouzas I, Sgourakis G, Radtke A, Bockhorn M, Nadalin S, Treckmann J, Niebel W, Baba H A, Broelsch C E, Paul A
Department of General, Visceral, and Transplantation Surgery, University Hospital Essen, Essen, Germany; Department of General and Abdominal Surgery, Johannes Gutenberg University Hospital, Mainz, Germany.
Transplant Proc. 2008 Nov;40(9):3194-5. doi: 10.1016/j.transproceed.2008.08.053.
Intrahepatic cholangiocarcinoma (ICC) is not a widely accepted indication for orthotopic liver transplantation (OLT). The present study describes our institutional experience with patients who underwent transplantation for ICC as well as those with ICC who underwent transplantation with the incorrect diagnosis of hepatocellular carcinoma (HCC).
Data corresponding to ICC patients were reviewed for the purposes of this study. Patients with hilar cholangiocarcinoma and incidentally found ICC after OLT for benign diseases were excluded from further consideration.
Among the 10 patients, 6 underwent transplantation before 1996 and 4 after 2001. Those who underwent transplantation in the early period had a preoperative diagnosis of inoperable ICC (n = 4) and ICC in the setting of primary sclerosing cholangitis (n = 2). In the latter period the subjects had a diagnosis of HCC in cirrhosis (n = 3) or recurrent ICC after an extended right hepatectomy (n = 1). Median survival was 25.3 months for the whole series and 32.2 months (range, 18-130 months) when hospital mortality was excluded (n = 3). Four patients are currently alive after 30, 35, 42, and 130 months post-OLT, respectively. Two patients died of tumor recurrence at 18 and 21 months post-OLT, respectively. One-, 3-, and 5-year survival rates were 70%, 50%, and 33%, respectively.
The role of OLT in the setting of ICC may be re-evaluated in the future under strict selection criteria and with prospective multicenter randomized studies. Potential candidates to be included are those with liver cirrhosis and no hilar involvement who meet the Milan criteria for HCC.
肝内胆管癌(ICC)并非原位肝移植(OLT)广泛认可的适应证。本研究描述了我们机构对因ICC接受移植的患者以及那些被误诊为肝细胞癌(HCC)而接受移植的ICC患者的经验。
为本研究目的,回顾了与ICC患者相关的数据。肝门部胆管癌患者以及OLT治疗良性疾病后偶然发现ICC的患者被排除在进一步研究之外。
10例患者中,6例在1996年前接受移植,4例在2001年后接受移植。早期接受移植的患者术前诊断为无法手术切除的ICC(n = 4)和原发性硬化性胆管炎合并ICC(n = 2)。后期患者诊断为肝硬化合并HCC(n = 3)或扩大右肝切除术后复发性ICC(n = 1)。整个系列的中位生存期为25.3个月,排除医院死亡患者(n = 3)后为32.2个月(范围18 - 130个月)。4例患者分别在OLT后30、35、42和130个月时仍存活。2例患者分别在OLT后18和21个月死于肿瘤复发。1年、3年和5年生存率分别为70%、50%和33%。
未来可能需要在严格的选择标准下通过前瞻性多中心随机研究对OLT在ICC中的作用进行重新评估。潜在的纳入对象可能是符合HCC米兰标准、有肝硬化且无肝门部受累的患者。